Carlos Arteaga

Three breast cancer investigators from Vanderbilt-Ingram Cancer Center (VICC) have been awarded research grants from Susan G. Komen, a nonprofit foundation devoted to supporting cancer research, community health outreach, advocacy and public policy initiatives. Read More

Thanks to advances in treatment, the relative five-year survival rate from all combined subtypes of breast cancer now exceeds 90 percent and yet the disease remains the third leading cause of cancer deaths in the United States after lung and colorectal cancers. Read More

Carlos L. Arteaga, M.D., director of the Center for Cancer Targeted Therapies (C2T2), director of the Breast Cancer Research Program and associate director for Clinical Research at Vanderbilt-Ingram Cancer Center (VICC), has been named director of the Harold C. Simmons Comprehensive Cancer Center and associate dean of Oncology Programs at the UT Southwestern Medical Center in Dallas. Read More

The ability to test patients’ cancers for individual differences, mainly at the genetic level, and to make treatment decisions based on those differences is the hallmark of precision medicine, and Vanderbilt University Medical Center (VUMC) is among the leaders of this new approach to diagnosis and treatment. Read More

For more than twenty years, Vanderbilt-Ingram Cancer Center’s (VICC) primary source of outside funding has been provided by the National Institutes of Health. But in breast cancer, Susan G. Komen, a nonprofit dedicated to breast cancer research and community services, has been a significant sponsor of research and patient care support. Read More

Carlos L. Arteaga, M.D., the Donna S. Hall Professor of Breast Cancer and director of the Center for Cancer Targeted Therapies and the Breast Cancer Program at Vanderbilt-Ingram Cancer Center (VICC), has been recognized for his cancer research efforts by the American-Italian Cancer Foundation (AICF). Read More

Valerie Malyvanh Jansen, M.D., Ph.D., a third-year medical oncology fellow, recently received several national awards and grants, as well as a Vanderbilt-Ingram Cancer Center fellowship, in recognition of her translational cancer research. Read More

New “tumor in a dish” technology is poised to assess rapidly how effective specific anticancer cocktails will be on an individual’s cancer before chemotherapy begins. Read More

Carlos L. Arteaga, M.D., director of the Center for Cancer Targeted Therapies and director of the Breast Cancer Program at Vanderbilt-Ingram Cancer Center (VICC), has been named a fellow of the AACR Academy. Read More

Two leading cancer organizations are calling for regulation of e-cigarettes and other electronic nicotine delivery systems (ENDS). Read More

A group of Vanderbilt-led investigators has identified a new gene mutation that may explain why some breast cancer patients do not respond to anti-hormone therapy. Read More

A team of biomedical engineers has developed a new "tumor-in-a-dish" technology that promises to improve the effectiveness of chemotherapy. Read More

There are now approximately 14.5 million cancer survivors in the United States, thanks in large part to advances in cancer research and the development of new anti-cancer therapies. Read More

Two Vanderbilt-Ingram Cancer Center investigators have received multi-year breast cancer research grants from the Susan G. Komen for the Cure Breast Cancer Foundation. Read More

Carlos L. Arteaga, M.D., professor of Medicine and Cancer Biology and Donna S. Hall Professor of Breast Cancer Research at Vanderbilt-Ingram Cancer Center (VICC), assumed the presidency of the American Association for Cancer Research (AACR) for 2014-2015 during the group’s annual meeting last week in San Diego. Read More

Eighteen academic and administrative leaders at Vanderbilt University have been elected fellows of the American Association for the Advancement of Science (AAAS) this year. Read More

Vanderbilt-Ingram Cancer Center’s Breast Specialized Program of Research Excellence (SPORE) has been awarded a third round of funding from the National Cancer Institute (NCI). Read More

Vanderbilt-Ingram Cancer Center leaders formally dedicated the space for the new Center for Cancer Targeted Therapies (CCTT), located in the Infusion Center on the second floor of The Vanderbilt Clinic, at a special ribbon-cutting held during last week’s fall meeting of the Cancer Center’s Board of Overseers. Read More

Vanderbilt-Ingram Cancer Center investigators are receiving $1 million in breast cancer research grant funds from Susan G. Komen, the largest nonprofit foundation supporting breast cancer research. Read More

Carlos Arteaga, M.D., professor of Medicine and Cancer Biology, has been appointed to lead two newly created cancer research initiatives at the Vanderbilt-Ingram Cancer Center. Read More